INIT — Initiator Pharma A/S Share News
0.000.00%
Last trade - 00:00- SEK195.09m
- SEK176.92m
Brief: Initiator Pharma Q4 Operating Loss Widens To DKK 7.3 Mln
Brief: Initiator Pharma Gets CTA Approval For IPTN2021 Program Phase I Study
Brief: Initiator Pharma Q3 EBIT Loss Widens To DKK 9.1 Million
Brief: Initiator Pharma Q2 EBIT Loss Widens To DKK 4.9 Mln
Brief: Initiator Pharma Proposes Directed Issue And Fully Guaranteed Preferential Rights Issue
Brief: Initiator Pharma Q4 Operating Loss Narrows To DKK 2.0 Mln
Brief: Initiator Receives SEK 8.9 Mln Trough Exercise Of Warrants
Brief: Initiator Pharma Secures Funding For IPED2015 Clinical Phase 2b Study
Brief: Initiator Pharma A/S - Q3 EBIT Was Tdkk -3,068
Brief: Initiator Pharma Receives Grant From Innovation Fund Denmark
Brief: Initiator Pharma Q2 EBIT Loss Narrows To DKK 3.0 Mln
Brief: Initiator Pharma Gets Approval To Start Phase 2a Trial For IP2018
Brief: Initiator Pharma Raises SEK 6.96 Million Through Issue Of Units
Brief: Initiator Pharma Q1 EBIT Loss Widens To DKK 2.4 Mln
Brief: Initiator Pharma Performs Directed Issue, Suggests Fully-guaranteed Rights Issue
Brief: Initiator Pharma Q4 EBIT Loss Stable at DKK 2.5 Mln
Brief: Initiator Pharma Reports Positive Phase IIa Clinical Data For IPED2015 In Patients With Severe Erectile Dysfunction
Brief: Initiator Pharma Q3 EBIT Loss Narrows To DKK 2.0 Mln
Brief: Initiator Pharma: Draft Data From IPED2015 Study Expected In December